Determinants of serious health outcome‐free status in middle‐aged and older people with dysglycaemia: Exploratory analysis of the Outcomes Reduction with an Initial Glargine Intervention (ORIGIN) trial
Authors' conclusion
A set of routinely measured clinical characteristics and seven protein biomarkers identify middle-aged and older people with prediabetes or early type 2 diabetes as least likely to experience serious outcomes during follow-up.
Study context
- Population
- Middle-aged and older adults with prediabetes and early T2D from 40 countriesbiomarker subset 8401
- Participants
- 12,537 participants
- Primary endpoint
- Serious outcome-free status: absence of major cardiovascular outcomes, kidney or retinal outcomes, peripheral artery disease, dementia, cancer, any hospitalization, or death
- Follow-up
- Median 6.2 years (IQR 5.8, 6.7)
Methodological detailsexploratory analysis
- Exploratory analysis
Primary result
As reported in the abstract
Remained free of serious outcomes
Participants who remained free of serious outcomes
3328
26.6%
Clinical determinants plus biomarkers: C-statistic
0.71
95% CI 0.70–0.73
Clinical determinants plus biomarkers: net reclassification improvement
0.55
95% CI 0.48–0.58
Original publication
Determinants of serious health outcome‐free status in middle‐aged and older people with dysglycaemia: Exploratory analysis of the ORIGIN trial. Diabetes Obes Metab. Published 15 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →